severe eosinophilic asthma
Respiratory · 2016–2020
8decisions
2medicines
5carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| benralizumab Treatment of uncontrolled severe eosinophilic asthma. New presentation (pre-filled pen/auto-injector form) as a treatment option. | Mar 2020 | Recommended with restriction | input received Asthma Australia |
| mepolizumab Treatment of uncontrolled severe eosinophilic asthma in patients aged 12 years and over. This submission sought listing of new presentations (pre-filled pen… | Mar 2020 | Recommended with restriction | input received Asthma Australia |
| benralizumab Treatment of uncontrolled severe eosinophilic asthma in patients aged 12 years and over as an add-on maintenance treatment. | Mar 2018 | Recommended | none received |
| mepolizumab Treatment of uncontrolled severe eosinophilic asthma in patients aged 12 years and over. | Mar 2018 | Deferred | input received Thoracic Society |
| benralizumab Treatment of uncontrolled severe eosinophilic asthma in patients aged 18 years and over as an add-on to inhaled corticosteroids and long-acting beta-agonists. | Mar 2018 | Recommended with restriction | input received Asthma Australia |
| mepolizumab Uncontrolled severe eosinophilic asthma in patients aged 12 years and over. The submission requested extending the validity period for the eosinophil blood… | Nov 2017 | Recommended | none received |
| mepolizumab Treatment of severe eosinophilic asthma in patients aged 12 years and over. | Jul 2016 | Recommended with restriction | none received |
| mepolizumab Treatment of severe eosinophilic asthma in patients aged 12 years and over with inadequate control despite optimised asthma therapy. | Mar 2016 | Not recommended | 2 individuals National Asthma Council Australia |
Who spoke
Asthma Australia · Thoracic Society · National Asthma Council Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.